What Ceolia Pharma does

Ceolia Pharma Co., Ltd. (セオリア ファーマ株式会社) is a Tokyo-based specialty pharmaceutical company founded in April 2010 as a joint venture between Aska Pharmaceutical Co., Ltd. and Senju Pharmaceutical Co., Ltd., with Senju remaining the major shareholder. The company is purpose-built around the ENT (Ear, Nose, Throat) therapeutic area, marketing itself as a pioneer ENT-focused pharma in Japan and serving otolaryngology specialists, hospitals, clinics, and pharmacies through a sales-led model supplemented by co-promotion and exclusive distribution partnerships with major Japanese pharmaceutical companies.

Ceolia's product portfolio is narrow but vertically deep within ENT: antibacterial ear drops (Comlex® Ear Preparation 1.5%, levofloxacin hydrate, launched 2023), an earwax removal agent (Dioctyl Sodium Sulfosuccinate Ear Preparation 5% CEO, launched 2015), leukotriene receptor antagonists for bronchial asthma and allergic rhinitis (Montelukast Tablets 5mg/10mg CEO, launched 2016), a home-use nasal mucosa protective agent (Nasaleze®, launched 2022, distributed via a dedicated consumer site), and a dust mite sublingual immunotherapy tablet (Asitea® Mite Sublingual Tablets, promotion started 2025). The underlying technology is conventional small-molecule and allergen immunotherapy formulation, with the company holding Class 1 and Class 2 pharmaceutical manufacturing and sales licenses plus a controlled medical device sales permit in Japan.

The business model is prescription-pharmaceutical sales in Japan at government-regulated drug prices, with revenue generated through direct field sales to medical institutions and via channel partners — most notably an exclusive sales contract with Takeda Pharmaceutical (2014), co-promotion partnerships with Senju, Takada, and Stallergenes Greer/Shionogi, and joint development with NanoCarrier (now NANO MRNA). Headcount is 65 employees, registered capital is ¥30 million, and the company operates from a central Tokyo headquarters, a Tokyo sales/marketing office, and a Saitama-based logistics center. The company is privately held with no public listing or disclosed external funding rounds.

Name

Ceolia Pharma

Legal name

Ceolia Pharma Co., Ltd.

Website

https://ceolia.co.jp

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Short description

Ceolia Pharma is a Tokyo-based specialty pharmaceutical company founded in 2010, focused exclusively on ENT (ear, nose, throat) therapeutics for Japanese medical institutions and patients via a 65-person sales-led operation, distribution partnerships with Takeda and Senju, and a small portfolio of prescription products plus a home-use nasal brand (Nasaleze).

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals (ENT / Otolaryngology)

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Respiratory & Allergy Pharmaceuticals (HLAIAAAH), General Otolaryngology (ENT) (HLAKAMAA), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• ENT specialty pharmaceuticals
• Otolaryngology therapeutics
• Prescription ear drops
• Sublingual immunotherapy tablets
• Nasal mucosal protectors

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Sales: Development, manufacturing, and sales of prescription pharmaceuticals and medical devices, primarily in the ENT (Ear, Nose, Throat) specialty area.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Ceolia Pharma develops, manufactures, and sells prescription pharmaceuticals and medical devices focused exclusively on the otolaryngology (ENT) specialty area, including antibacterial ear drops, earwax removers, leukotriene receptor antagonists, sublingual allergen immunotherapy tablets, and a home-use nasal mucosal protector. The company's products are sold primarily to medical institutions, ENT specialists, hospitals, and pharmacies in Japan through its own field force and an exclusive sales agreement with Takeda Pharmaceutical.

Product overview

Ceolia Pharma is an ENT (Ear, Nose, Throat) specialty pharmaceutical company founded in 2010. The company operates as a single-brand specialty pharma offering prescription medications primarily for ENT conditions. The product portfolio includes antibacterial ear drops (Comlex®), ear wax removers, leukotriene receptor antagonists (Montelukast), dust mite sublingual immunotherapy tablets (Ashi Tea®), and a home-use nasal mucosal protector (Nasaleze®). All products are focused on the ENT specialty area, positioning the company as a dedicated ENT-focused specialty pharma.

Differentiator

Problem solved

Functional benefit

Brands

• Nasaleze: Household nasal mucosa protective agent
• Comlex (抗菌耳科用製剤)

Products and services

• Comlex® Ear Preparation 1.5% (コムレクス®耳科用液1.5%) Antibacterial ear drops containing levofloxacin hydrate for the treatment of ear infections. Sold as a prescription ENT specialty pharmaceutical to medical institutions in Japan.
• Nasaleze® (ナサリーズ) Home-use nasal mucosal protector for patients with nasal conditions. Distributed through a dedicated consumer website and household channels in Japan.
• Montelukast Tablets 5mg/10mg CEO (モンテルカスト錠5mg/10mg「CEO」) Leukotriene receptor antagonist tablets for the treatment of bronchial asthma and allergic rhinitis, available in 5mg and 10mg dosage strengths. Sold as a prescription ENT/respiratory specialty pharmaceutical.
• Asitea® Dust Mite Sublingual Tablets 100 Units (IR) / 300 Units (IR) (アシテア®ダニ舌下錠) Sublingual allergen immunotherapy tablets for dust mite allergy, used as an ENT/respiratory specialty treatment for house dust mite allergic rhinitis.
• Dioctyl Sodium Sulfosuccinate Ear Preparation 5% CEO (ジオクチルソジウムスルホサクシネート耳科用液5%「CEO」) Ear wax (cerumen) remover solution used in ENT clinical practice for cerumen removal. Sold as a prescription ENT specialty pharmaceutical in Japan.

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core and minor.

• 千寿製薬株式会社 (Senju Pharmaceutical Co., Ltd.)coreStrategic or Co-development Partner · 1 January 2010Major shareholder and co-founder of Ceolia Pharma. Established through joint investment by Senju Pharmaceutical and Askas Pharmaceutical in April 2010. In 2025, entered into a comprehensive business partnership agreement.
• 武田薬品工業株式会社 (Takeda Pharmaceutical Co., Ltd.)coreChannel Partner/ Reseller/ DistributorExclusive sales contract for Ceolia Pharma products, established in 2014.
• ナノキャリア株式会社 / NANO MRNA株式会社 (NanoCarrier Co., Ltd. / NANO MRNA Co., Ltd.)minorStrategic or Co-development PartnerJoint development agreement signed in May 2018 for pharmaceutical product development.
• 高田製薬株式会社 (Takada Pharmaceutical Co., Ltd.)minorStrategic or Co-development PartnerBusiness partnership agreement signed in 2022.
• あすか製薬株式会社 (Askas Pharmaceutical Co., Ltd.)coreStrategic or Co-development PartnerCo-founder of Ceolia Pharma, established through joint investment with Senju Pharmaceutical in 2010.
• Stallergenes Greer / 塩野義製薬株式会社 (Shionogi & Co., Ltd.)minorGTM or Marketing PartnerPromotion partner for Asitea® Mite Sublingual Tablets (アシテア®ダニ舌下錠), with promotion company change announced in July 2025.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Maruho: Maruho is a Japanese specialty pharma with a deep dermatology franchise and a long history of operating as a focused specialty company, sharing Ceolia's model of concentrating on a single therapeutic area with strong KOL engagement.
• Stallergenes Greer: Stallergenes Greer is a global allergen immunotherapy specialist and Ceolia's promotion partner for Asitea Mite Sublingual Tablets. It is directly comparable in the sublingual immunotherapy category that Ceolia is now commercializing in Japan.
• Kyorin Pharmaceutical: Kyorin is a Japanese specialty pharma with a long-standing respiratory and ENT focus, including products in otolaryngology and allergic disease. Its franchise overlap with Ceolia in respiratory/allergy makes it one of the most directly comparable specialty peers.
• Senju Pharmaceutical: Senju is Ceolia's co-founder and major shareholder, also a Japanese specialty pharma with deep focus on ophthalmology and ENT therapeutics. It is the most directly comparable peer given the overlapping therapeutic franchise and shareholder relationship.
• Torii Pharmaceutical: Torii is a Japanese specialty pharma focused on dermatology, allergies, and renal disease, with presence in allergen immunotherapy and ENT-adjacent categories. Its niche-specialty GTM model and allergy product overlap make it a direct comparable to Ceolia.
• Nippon Shinyaku: Nippon Shinyaku is a Japanese specialty pharma with a focused franchise including respiratory and allergy therapeutics, and a similar small-but-differentiated operating model. Comparable in therapeutic area mix and specialty-pharma positioning.

Broad incumbents

• Daiichi Sankyo: Daiichi Sankyo is a large Japanese pharma with a meaningful specialty and prescription pharmaceutical franchise, including respiratory products. It is comparable as a broad incumbent that competes with Ceolia's products in the Japanese prescription market.
• Santen Pharmaceutical: Santen is a large Japanese specialty pharma focused on ophthalmology, operating a similar single-therapeutic specialty model to Ceolia but at much greater scale. It is a useful benchmark for how a Japan-based specialty pharma builds a defensible franchise around a defined therapeutic area.
• Shionogi & Co. Shionogi is a major Japanese pharma that, together with Stallergenes Greer, supports promotion of Asitea in Japan. As a broad-incumbent Japanese pharma with allergy/ENT overlap, it provides a benchmark for partner-of-record dynamics.

Others

• Aska Pharmaceutical: Aska is the other co-founder of Ceolia, a Japanese pharma with focus on women's health and obstetrics. Although not directly overlapping in ENT, its historical co-ownership relationship and similar mid-sized Japanese pharma profile make it a relevant ecosystem peer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ceolia Pharma